EDUCATION AND TRAINING

Clinical Fellowship in Cardiology, Johns Hopkins Hospital, National Institutes of Health, 1990-1992.

A.B. (Magna cum laude), Romance Languages and Literatures, Princeton University, Princeton, New Jersey, 1976.

Residency in Internal Medicine, Massachusetts General Hospital, 1984-1987.

M.D., University of California, Los Angeles, 1984.

David A. Dichek M.D., F.A.H.A.
Associate Director for Research
Professor of Medicine, Adjunct Professor of Pathology
John L. Locke, Jr. Family Endowed Chair in Cardiovascular Research and Treatment

BOARD CERTIFICATION

American Board of Internal Medicine, Cardiovascular Disease, 1993-2003; 2004-2014.

American Board of Internal Medicine, 1987-present.

AREAS OF CLINICAL EXPERTISE

General cardiology

CURRENT RESEARCH INTERESTS

Gene transfer to blood vessels

Gene therapy for cardiovascular disease

Vascular biology with a focus on the contributions of the plasminogen / plasminogen activator system and transforming growth factor beta to vascular disease

for more information see: http://depts.washington.edu/cardweb/dichekLab.shtml

SPECIAL ACCOMPLISHMENTS

Special Recognition Award, ATVB Council of the American Heart Association, 2008.

John Locke Jr., Family Endowed Chair in Cardiovascular Research and Treatment, 2001-present.

Fellow of the American Heart Association, 2001-present.

Editorial Boards: Circulation, 1996-2008; Circulation Research, 1996-2008; Human Gene Therapy, 1998-present; Arteriosclerosis, Thrombosis, and Vascular Biology, 2001-present.

Vascular Biology I Study Section, National AHA, 1995-1999.

Pathology A Study Section, NIH, 1999-2001.

Ad hoc reviewer, Recombinant DNA Advisory Committee, NIH, 2000.

Phi Beta Kappa, Princeton University, 1976.

Stafford Warren Medal, UCLA Medical School, given to the graduating student with the highest academic ranking, 1984.

RECENT PUBLICATIONS

Frutkin AD, Otsuka G, Stempien-Otero A, Sesti C, Du L, Jaffe M, Dichek HL, Pennington CJ, Edwards DR, Nieves-Cintron M, Minter D, Preusch M, Hu JH, Marie JC, Dichek DA. TGF-β1 limits plaque growth, stabilizes plaque structure, and prevents aortic dilation in Apolipoprotein E-null mice. Arterioscler. Thromb. Vasc. Biol. 2009;29:1251-1257.

Kremen M, Krishnan R, Emery I, Hu JH, Slezicki KI, Wu A, Qian K, Du L, Plawman A, Stempien-Otero A, Dichek DA. Plasminogen mediates the atherogenic effects of macrophage-expressed urokinase and accelerates atherosclerosis in apoE-knockout mice. Proc. Natl. Acad. Sci. USA 105:17109-17114, 2008.

Stempien-Otero A, Plawman A, Meznarich J, Dyamenahalli T, Otsuka G, Dichek DA. Mechanisms of Cardiac Fibrosis Induced by Urokinase Plasminogen Activator. J. Biol. Chem. 281(22):15345-15351, 2006.

Otsuka G, Agah R, Frutkin AD, Wight TN, Dichek DA. Transforming Growth Factor β1 Induces Neointima Formation Through Plasminogen Activator Inhibitor-1-Dependent Pathways. Arterioscl. Thromb. Vasc. Biol. 26:737-743, 2006.

Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA. Overexpression of Urokinase by Macrophages or Deficiency of Plasminogen Activator Inhibitor Type 1 Causes Cardiac Fibrosis in Mice. Circ. Res. 95:637-644, 2004.

Cozen AE, Moriwaki H, Kremen M, DeYoung MB, Dichek HL, Slezicki KI, Young SG, Veniant M, Dichek DA. Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation. 109:2129-2135, 2004.

Wen S, Graf S, Massey PG, Dichek DA. Improved vascular gene transfer with a helper-dependent adenoviral vector. Circulation. 110:1484-1491, 2004.

Falkenberg M, Tom C, DeYoung MB, Wen S, Linnemann R, Dichek DA. Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth. Proc. Natl. Acad. Sci. USA 99:10665-10670, 2002.